Company Dynamics - Guangzhou Xiangxue Pharmaceutical Co., Ltd. (ST Xiangxue) is facing multiple challenges, with over 92.26 million yuan in litigation amounts disclosed in the past year, accounting for 8.78% of the company's latest audited net assets [2] - The company has been involved in significant legal disputes, including a contract dispute amounting to 20.92 million yuan and a financial loan dispute totaling 44.96 million yuan [2] - Established in 1986, ST Xiangxue has developed a full industry chain from traditional Chinese medicine cultivation to production and distribution, with core products including medicinal syrups and granules [2] Financial Performance - Since 2016, ST Xiangxue's net profit has declined significantly, with a drop of over 60% in 2016 to 66.02 million yuan, and subsequent years maintaining net profits between 60 million and 70 million yuan [3] - The company reported a loss of 677 million yuan in 2021, followed by losses of 530 million yuan, 389 million yuan, and 859 million yuan in 2022, 2023, and 2024 respectively [3] - In January 2025, the company received a notice from creditor Guangdong Jinglong Construction Group, leading to a pre-restructuring application due to its inability to repay debts [3] Restructuring Efforts - The pre-restructuring process was approved by the Guangzhou Intermediate People's Court, initially set for three months but has faced multiple extensions, now extended to January 11, 2026 [3][4] - Despite ongoing restructuring efforts, the company projected a significant loss for 2025, estimating a net loss between 635 million yuan and 934 million yuan [4] - Contributing factors to the losses include intensified market competition, liquidity issues, high financial costs, and asset impairment provisions totaling approximately 130 million yuan [4][5]

作为一家成立于1986年的老牌中药企业，香雪制药在2010年12月于深交所上市。公司名称取自广州著名景点萝岗香雪。近年来，香雪制药致力于打造从中药 材种植到医药流通的全产业链布局，并开发了包括中药饮片、中成药、医疗器械和T细胞免疫治疗在内的多系列产品。 广州市香雪制药股份有限公司（证券代码：ST香雪，300147.SZ）近期陷入多重困境。根据最新公告，该公司及其子公司在过去一年中涉及的诉讼金额已超 过九千万元。截至2月8日，公司及子公司的诉讼案件累计金额约为9226.56万元，占其最近一期经审计净资产的8.78%。 除了小额案件外，主要的诉讼包括与广州万博佳诚创业投资合作企业之间的合同纠纷，涉案金额达2,092万元，以及与某银行金融借贷纠纷，涉案金额高达 4,496万元。由于部分案件仍在审理或未结案，具体的诉讼影响尚待进一步评估，因此对公司当期及未来的利润影响仍不确定。 公司动态 与此同时，香雪制药在2025年的业绩预告显示，预计全年归母净利润将亏损6.35亿元至9.34亿元，扣非净利润亏损6.12亿元至8.99亿元。造成这一亏损的主要 原因包括市场竞争加剧、流动性危机导致的收入减少和毛利率下降，以及高额的财 ...

公告称，上市公司及子公司涉及的诉讼，鉴于部分案件尚在法院审理中或尚未结案，案件影响金额尚需 进一步评估，诉讼案件对公司本期及期后利润的影响尚无法判断，具体以公司经审计的财务报告为准。 老牌中药企业广州市香雪制药股份有限公司(证券简称：ST香雪（300147），300147.SZ)身陷多重困 境，根据最新披露，上市公司及子公司过去一年涉讼金额超过九千万元。 据ST香雪2月8日公告，截至公告披露日，除已经披露的诉讼事项外，公司及子公司连续十二个月内作 为被告累计涉及的诉讼事项涉案金额合计约9226.56万元，占最近一期经审计净资产8.78%。除几万元至 几十万元的小额案件外，公司与广州万博佳诚创业投资合作企业的合同纠纷涉案金额达到2,092万元， 与中国农业银行股份有限公司化州市支行的金融借贷纠纷涉案金额达到4,496万元。 (经济观察网杜远/文) 上市初期的香雪制药净利润规模一度超过1亿元，但2016年后公司业绩开始下滑。2016年公司净利润同 比下跌超六成，为6602.41万元，2016年—2020年，公司净利润规模保持在6000万元-7000万元规模， 2021年则由盈转亏，当年出现大额亏损6.77亿元。2 ...

Core Viewpoint - Guangzhou Xiangxue Pharmaceutical Co., Ltd. and its actual controller Wang Yonghui have been penalized for information disclosure violations, with fines totaling 6 million yuan for the company and 10 million yuan for Wang Yonghui [2][3][10] Group 1: Violations and Penalties - The company failed to recognize losses from the demolition of villas in its 2019 annual report, resulting in an inflated profit of 53.83 million yuan, which accounted for 45.98% of the total profit for that year [4] - The actual controller Wang Yonghui received a warning and was fined 10 million yuan, with 3 million yuan as the directly responsible supervisor and 7 million yuan as the actual controller [2][3] - The company was also found to have significant omissions regarding non-operating fund occupation by related parties, amounting to 4.852 billion yuan from 2016 to 2020 [4] Group 2: Background and Investigation - The investigation into Xiangxue Pharmaceutical began on September 30, 2024, when the company and Wang Yonghui received a notice of case filing from the China Securities Regulatory Commission (CSRC) [3] - The violations were traced back to 2016, with the formal administrative penalty decision being disclosed on August 16, 2025, marking the end of the investigation phase [3][4] Group 3: Financial Performance and Market Impact - The company has reported continuous net losses from 2021 to 2024, with projected revenues for 2024 between 1.613 billion yuan and 2.013 billion yuan, and net losses estimated between 600 million yuan and 862 million yuan [6] - Following the penalties, the company's stock was suspended for one day and subsequently resumed trading under a risk warning, changing its name to "ST Xiangxue" [6] Group 4: Industry Context and Regulatory Environment - The case of Xiangxue Pharmaceutical is not isolated, as similar violations have occurred in the industry, highlighting a trend of increased scrutiny and penalties for information disclosure violations [7][10] - The new Securities Law implemented in 2020 has significantly increased the penalties for disclosure violations, with the company facing a fine of 6 million yuan and individual fines reaching up to 10 million yuan [10]